K36 Therapeutics Launches With $30 Million Series A Financing From F-Prime Capital And Atlas Venture With Eight Roads Ventures
K36 Therapeutics Launches With $30 Million Series A Financing From F-Prime Capital And Atlas Venture With Eight Roads Ventures
12/09/21, 7:00 AM
Location
cambridgeMoney raised
$30 million
Round Type
series a
K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing breakthrough therapies for the unmet medical needs of cancer patients, announced today its $30 million Series A financing co-led by F-Prime Capital and Atlas Venture with Eight Roads Ventures. The funds will be used to advance the company's lead candidate, KTX-1001, through its first clinical proof-of-concept studies. KTX-1001 is a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to a t(4;14) translocation
Company Info
Company
K36 Therapeutics ("K36")
Location
cambridge, maryland, united states
Additional Info
K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough therapies for the unmet medical needs of cancer patients worldwide.